Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Abroad (travel likely)RecruitingPHASE1

Conditions

Breast Cancer Metastatic

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
Contact: Study coordinator (Kayla Chamberlin, RN) · chamberlink@uthscsa.edu · 210-450-1000
Contact: Study coordinator (Kate Lathrop, MD) · lathrop@uthscsa.edu · 210-450-1000

Study leads

Kate Lathrop, MD
Principal Investigator
The University of Texas Health Science Center at San Antonio

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

PIK3CA Mutation · Solid Tumor, Adult · HER2-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Tucson, United States · San Diego, United States

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Oligometastatic Breast Carcinoma · Breast Cancer · Metastatic Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Basking Ridge, United States · Middletown, United States

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

La Jolla, United States

HER2-PET Imaging in HER2-low Breast Cancers

Breast Cancer Metastatic

Abroad (travel likely)RecruitingPHASE1, PHASE2

Sherbrooke, Canada